| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Patients with essential thrombocythemia (ET) without typical somatic mutations were classified into those with atypical MPL mutations and those with no mutation. Of these, the latter patients were mostly young women and were at low risk of thrombosis and secondary fibrosis. The blood cells of the patient exhibited polyclonal hematopoiesis, but the stem cells exhibited a capacity to form cell-autonomous megakaryocytic colonies. On the other hand, when Ba/F3 cells was transduced with wild-type MPL and cultured for several weeks in the absence of cytokine, cells gained a capacity to proliferate in the absence of cytokine associated with constitutive activation of MPL downstream molecules. These findings strongly suggested an existence of yet unidentified molecular mechanism for the MPL activation, which may play a role in the development of ET with no mutation.
|
